CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley OncologySTAT Editorial Team. Nov 23 2010

CML—The Changing Landscape of Front-line Therapy:
Interview With Dr. Jane Apperley
 Nov 23rd 2010
Abstract
Part I:  First-Line Therapy:  Imatinib vs newer agents
OncologySTAT:
Dr. Apperley, would you talk about the changing landscape of front-line therapy for treatment of newly diagnosed chronic-phase chronic myeloid leukemia (CML)? Is the treatment paradigm changing? If so, how will imatinib fit in with the introduction of secondary tyrosine kinase inhibitors (TKIs)?....more
http://oncologystat.com/viewpoints/when-the-smoke-clears/CML_New_Drugs_Part_I_Interview_With_Dr_Jane_Apperley.html
----------------------------------------------------------------------------------------------------------------

Part ll: What to do About Imatinib Resistance; When to Consider Transplant:
http://oncologystat.com/viewpoints/when-the-smoke-clears/CML_What_to_do_About_Imatinib_Resistance_When_to_Consider_Transplant_Part_II_Interview_With_Dr_Jane_Apperley.html